[VIEW] agent=Enterprise Data Platform & Security Lead | scenario_id=117 | rounds=20

--- Round 0 ---
[R0.1] Data Governance & Privacy Officer (speak, public): To assess the registry program's data-sharing feasibility, can we start by discussing the specific data elements and delivery cadence being requested?
[R0.2] Oncology Research Program Manager (speak, public): The registry involves 9 participating health systems, targeting 1,250 cases per year, with quarterly data submissions within 14 days after quarter-end. We're collecting 38 specific fields, including stage and regimen, but excluding imaging files. Our central IRB reliance request is pending, with a decision expected within 21 days.
[R0.3] Enterprise Data Platform & Security Lead (speak, public): The proposed quarterly data submissions with 38 specific fields should be manageable within our existing data pipeline design using Azure Data Lake Gen2 and SFTP drop with PGP encryption. However, can you clarify if there are any specific handling requirements or unusual content requests that we should be aware of for these 38 fields, and have there been any prior disclosure-related scrutiny or concerns regarding the data elements being collected?

--- Round 1 ---
[R1.1] Data Governance & Privacy Officer (speak, public): To ensure we're aligned on the data privacy and security aspects, can you confirm if the 38 fields being collected are within the permitted dataset elements as per our current guidelines, and are there any plans for auditing or monitoring the data transfer process through Azure Data Lake Gen2 and SFTP?
[R1.2] Oncology Research Program Manager (speak, public): We've confirmed that the 38 fields are within our permitted dataset elements. For auditing and monitoring, we plan to implement regular checks on the data transfer process through Azure Data Lake Gen2 and SFTP, ensuring compliance with our data governance policies. I'd like to know if there are any additional security measures or compliance requirements we should be aware of, especially considering the pending IRB decision and the involvement of multiple health systems.
[R1.3] Enterprise Data Platform & Security Lead (speak, public): To address the auditing and monitoring requirements, our existing data pipeline design includes access control patterns with service principals having least privilege access and key rotation every 180 days. We also have external connectivity constraints that limit outbound traffic to 2 IP allowlist entries, with a change request lead time of 10 business days. I need to confirm if these measures are sufficient for the multi-institutional data transfer and if there are any additional compliance requirements we need to adhere to, especially with the pending IRB decision.

--- Round 2 ---
[R2.2] Oncology Research Program Manager (speak, public): The Data Use Agreement negotiations are ongoing, with a few clauses still under discussion, particularly around data ownership and liability. We're working closely with our legal team to resolve these. Regarding the pending IRB decision, we're expecting a response within 21 days, which should help clarify any additional compliance requirements. I'd like to confirm if the proposed security measures and data transfer process meet the necessary standards for this multi-institutional registry.
[R2.3] Enterprise Data Platform & Security Lead (speak, public): To confirm whether our proposed security measures and data transfer process meet the necessary standards, I'd like to summarize that our data pipeline design uses Azure Data Lake Gen2 and SFTP drop with PGP encryption, and includes access controls with service principals having least privilege access. We also have constraints on outbound traffic limited to 2 IP allowlist entries. Given the multi-institutional nature of the registry and the pending IRB decision, are there any additional security or compliance requirements we should be aware of that could impact our implementation timeline or operational monitoring?

--- Round 3 ---
[R3.1] Data Governance & Privacy Officer (speak, private to=Oncology Research Program Manager,Enterprise Data Platform & Security Lead): To ensure we're on track with our primary objective, can we confirm if the outstanding DUA clauses around redisclosure, audit rights, and data destruction within 30 days have been addressed or are still pending? Additionally, are there any plans to conduct regular security audits or risk assessments on the data transfer process through Azure Data Lake Gen2 and SFTP?
[R3.2] Oncology Research Program Manager (speak, public): To address the outstanding DUA clauses and security audits, we're working closely with our legal team to finalize the Data Use Agreement, focusing on redisclosure, audit rights, and data destruction within 30 days. For security audits, we plan to conduct regular risk assessments on the data transfer process through Azure Data Lake Gen2 and SFTP, ensuring compliance with our data governance policies and any additional requirements stemming from the pending IRB decision. I'd like to confirm if these measures align with your expectations and if there are any further recommendations or concerns regarding the registry's data-sharing program.
[R3.3] Enterprise Data Platform & Security Lead (speak, public): To confirm alignment on the outstanding DUA clauses and security audits, our data pipeline design and access controls have been configured to meet the necessary security standards. However, I'd like to clarify if the planned regular risk assessments on the data transfer process through Azure Data Lake Gen2 and SFTP will include monitoring for any potential security findings similar to the recent pen test results, and if there are any plans to address potential redisclosure risks in the Data Use Agreement.

--- Round 4 ---
[R4.1] Data Governance & Privacy Officer (speak, public): To finalize our assessment of the registry program's data-sharing feasibility, can we confirm if the planned regular risk assessments and security audits will be documented and shared with our compliance team, and are there any further updates on the outstanding DUA clauses and the pending IRB decision?
[R4.2] Oncology Research Program Manager (speak, public): To finalize our discussion on the registry program's data-sharing feasibility, I've confirmed that we're on track with implementing regular risk assessments and security audits on the data transfer process. We're also working closely with our legal team to finalize the Data Use Agreement, focusing on outstanding clauses such as redisclosure, audit rights, and data destruction within 30 days. Given the pending IRB decision and the multi-institutional nature of the registry, I'd like to confirm if there are any further recommendations or concerns that could impact our implementation timeline or operational monitoring.
[R4.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our assessment on the registry program's data-sharing feasibility, I'd like to confirm that our proposed data pipeline design and security measures are aligned with the necessary standards for a multi-institutional registry. We've discussed the data elements, delivery cadence, and handling requirements. Given the pending IRB decision and the ongoing DUA negotiations, are there any remaining concerns or updates that could impact our implementation timeline or operational monitoring?

--- Round 5 ---
[R5.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, can we confirm if all parties are aligned on the data elements, delivery cadence, and security measures discussed, and are there any final updates on the outstanding DUA clauses and the pending IRB decision that could impact our approval?
[R5.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've confirmed that we're aligned on the data elements, delivery cadence, and security measures discussed. We're working closely with our legal team to finalize the Data Use Agreement, focusing on outstanding clauses such as redisclosure, audit rights, and data destruction within 30 days. Given the pending IRB decision and the multi-institutional nature of the registry, I believe we're on track to meet our primary objective. I'd like to confirm if there are any final updates or concerns that could impact our approval.
[R5.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've confirmed that our proposed data pipeline design using Azure Data Lake Gen2 and SFTP drop with PGP encryption, along with our access control patterns and external connectivity constraints, are aligned with the necessary standards for a multi-institutional registry. Given the progress on the Data Use Agreement and the pending IRB decision, I believe we're on track to meet our primary objective. I'd like to confirm if there are any final updates or concerns that could impact our approval.

--- Round 6 ---
[R6.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've reviewed the discussions on data elements, delivery cadence, and security measures. Given the progress on the Data Use Agreement and the pending IRB decision, I believe we have sufficient information to assess the contractual and privacy risks. Let's summarize our findings and confirm if we're ready to approve the program.
[R6.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've confirmed that we're aligned on the data elements, delivery cadence, and security measures discussed. We're working closely with our legal team to finalize the Data Use Agreement, focusing on outstanding clauses such as redisclosure, audit rights, and data destruction within 30 days. Given the pending IRB decision and the multi-institutional nature of the registry, I believe we're on track to meet our primary objective. I'd like to confirm if there are any final updates or concerns that could impact our approval.
[R6.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've confirmed that our proposed data pipeline design using Azure Data Lake Gen2 and SFTP drop with PGP encryption, along with our access control patterns and external connectivity constraints, are aligned with the necessary standards for a multi-institutional registry. Given the progress on the Data Use Agreement and the pending IRB decision, I believe we're on track to meet our primary objective. Let's summarize our findings and confirm if we're ready to approve the program.

--- Round 7 ---
[R7.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R7.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I've confirmed that we're aligned on the data elements, delivery cadence, and security measures discussed. We're working closely with our legal team to finalize the Data Use Agreement, focusing on outstanding clauses such as redisclosure, audit rights, and data destruction within 30 days. Given the pending IRB decision and the multi-institutional nature of the registry, I believe we're on track to meet our primary objective. Let's summarize our findings and confirm if we're ready to approve the program.
[R7.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings: we've confirmed the data elements, delivery cadence, and security measures are aligned with the necessary standards. The Data Use Agreement is nearing completion, and we're awaiting the IRB decision. Given this progress, I believe we're ready to approve the program pending the finalization of the DUA and IRB approval.

--- Round 8 ---
[R8.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R8.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I believe we've made significant progress. We've confirmed the data elements, delivery cadence, and security measures are aligned with the necessary standards. The Data Use Agreement is nearing completion, and we're awaiting the IRB decision. Given this progress, I'm inclined to approve the program pending the finalization of the DUA and IRB approval. Let's summarize our findings and confirm our readiness to approve the program.
[R8.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, I believe we've made significant progress. We've confirmed the data elements, delivery cadence, and security measures are aligned with the necessary standards. The Data Use Agreement is nearing completion, and we're awaiting the IRB decision. Given this progress, I'm inclined to approve the program pending the finalization of the DUA and IRB approval. Let's summarize our findings and confirm our readiness to approve the program.

--- Round 9 ---
[R9.1] Data Governance & Privacy Officer (speak, public): Let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R9.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings: we've confirmed the data elements, delivery cadence, and security measures are aligned with the necessary standards. The Data Use Agreement is nearing completion, and we're awaiting the IRB decision. Given this progress, I believe we're ready to approve the program pending the finalization of the DUA and IRB approval.
[R9.3] Enterprise Data Platform & Security Lead (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 10 ---
[R10.1] Data Governance & Privacy Officer (speak, public): Let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R10.2] Oncology Research Program Manager (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R10.3] Enterprise Data Platform & Security Lead (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 11 ---
[R11.1] Data Governance & Privacy Officer (speak, public): Let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R11.2] Oncology Research Program Manager (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R11.3] Enterprise Data Platform & Security Lead (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 12 ---
[R12.1] Data Governance & Privacy Officer (speak, public): Let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R12.2] Oncology Research Program Manager (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R12.3] Enterprise Data Platform & Security Lead (speak, public): Let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 13 ---
[R13.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R13.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R13.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 14 ---
[R14.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R14.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R14.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 15 ---
[R15.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R15.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R15.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 16 ---
[R16.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R16.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R16.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 17 ---
[R17.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R17.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R17.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 18 ---
[R18.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R18.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R18.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

--- Round 19 ---
[R19.1] Data Governance & Privacy Officer (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and assess if we're ready to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R19.2] Oncology Research Program Manager (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.
[R19.3] Enterprise Data Platform & Security Lead (speak, public): To finalize our recommendation on the registry program's data-sharing feasibility, let's summarize our key findings and confirm our readiness to approve the program based on the data elements, delivery cadence, security measures, and the status of the Data Use Agreement and IRB decision.

